Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (CRPC)
Conditions
Keywords
radioligand therapy, Pb-212, castrate-resistant prostate cancer, alpha particles, metastatic, mCRPC, Lu-177
Brief summary
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose escalation to identify a recommended dose and dose expansion to further assess safety and anti-tumour activity. Primary objectives are to characterize the safety profile and determine the optimal dose and schedule for future studies
Interventions
DRUGAB001
Pb-212 PSMA targeted alpha radioligand therapy
Sponsors
ARTBIO Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an open-label, noncontrolled, multinational, multicentre, interventional Phase 1 clinical study of AB001 in patients with advanced mCRPC. The study includes the following main parts: Dose Escalation: To assess the safety and tolerability of AB001 and determine the recommended dose level and treatment schedule in both 177Lu-PSMA naïve and 177Lu-PSMA experienced groups to take into the Expansion part. Dose Expansion: To further characterise the antitumour activity and safety profile of the recommended dose and schedule in both 177Lu-PSMA naïve and 177Lu-PSMA experienced groups for further development of AB001 in specific patient populations. Dose Escalation will seamlessly progress into Dose Expansion. The study will include several sub-studies to enable characterisation of the biodistribution, body clearance, and PK of AB001 in participants with mCRPC.
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male participants at least 18 years of age * ECOG PS of 0 to 2 * Progressive mCRPC * Previous treatment with at least one novel ARPI * Prior orchiectomy and/or prior or ongoing androgen-deprivation therapy * Prior treatment with at least one taxane regimen or patient refusing or considered appropriate by treating physician to delay taxane therapy * 177Lu-PSMA experienced Group only: Prior treatment with at least one dose of 177Lu-PSMA * At least one PSMA-avid distant metastatic lesion * Adequate bone marrow, renal, and hepatic function
Exclusion criteria
* Blockage in the bladder or kidneys * Untreated or uncontrolled brain metastases. Treated brain metastases are permitted provided they are neurologically stable * Symptomatic, or clinical or radiologic findings indicative of impending cord compression. * History of myelodysplastic syndrome (MDS), treatment-related acute myeloid leukaemia or features suggestive of MDS/acute myeloid leukaemia. * A known additional malignancy that has required active treatment within the past two years before start of study treatment, except for adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ that has undergone curative therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the safety and tolerability profile of AB001 in participants with mCRPC | From enrolment to active follow-up at 12 months post end of treatment | Incidence and severity of TEAEs (including AESIs and TESAEs) |
| Dose Escalation: To determine recommended AB001 Dose (MBq) in both 177Lu-PSMA naïve and 177Lu-PSMA experienced participants for Dose Expansion | For 177Lu-PSMA naïve group: Anticipated after 20 evaluable participants; ~1 year from FPFV in this group. For 177Lu-PSMA experienced group: Anticipated after 20 evaluable participants, ~1 year from FPFV in this group | The recommended dose (MBq) of AB001 for dose expansion in 177Lu-PSMA naïve and experienced groups, determined based on safety and preliminary antitumour activity assessments (including incidence of DLTs and PSA50 response). The multiple measurements will be aggregated by the study team to select a single recommended dose. Single Outcome Measure Value (Units): Dose in MBq |
| Dose Escalation: To determine recommended AB001 Schedule (frequency of dose in cycles/weeks) in both 177Lu-PSMA naïve and 177Lu-PSMA experienced participants for Dose Expansion | Time Frame- For 177Lu-PSMA naïve group: Anticipated after 20 evaluable participants; ~1 year from FPFV in this group. For 177Lu-PSMA experienced group: Anticipated after 20 evaluable participants, ~1 year from FPFV in this group | The recommended AB001 Schedule (frequency of dose in cycles/weeks) for dose expansion in 177Lu-PSMA naïve and experienced groups, determined based on safety and preliminary antitumour activity assessments (including incidence of DLTs and PSA50 response). The multiple measurements will be aggregated by the study team to select a single recommended AB001 Schedule. Single Outcome Measure Value (Units): AB001 Schedule in Cycles/weeks |
| Dose Expansion: To assess the recommended Dose (MBq) determined in Dose Escalation in both 177Lu-PSMA naïve and 177Lu-PSMA experienced participants for further clinical development of AB001 | In each group treated with selected dose, anticipated after 20 evaluable participants, ~1 year from FPFV in each group. | The recommended dose (MBq) of AB001 for further clinical development of AB001 in 177Lu-PSMA naïve and experienced groups, determined based on safety and preliminary antitumour efficacy (including incidence and severity of \[S\]AEs, PSA50 response, and ORR). The multiple measurements will be aggregated by the study team to select a single recommended dose. Single Outcome Measure Value (Units): Dose in MBq |
| Dose Expansion: To assess the recommended AB001 Schedule (frequency of dose in cycles/weeks) determined in Dose Escalation in both 177Lu-PSMA naïve and 177Lu-PSMA experienced participants for further clinical development of AB001 | In each group treated with selected schedule, anticipated after 20 evaluable participants, ~1 year from FPFV in each group. | The recommended schedule of AB001 for further clinical development of AB001 in 177Lu-PSMA naïve and experienced groups, determined based on safety and preliminary antitumour efficacy (including incidence and severity of \[S\]AEs, PSA50 response, and ORR). The multiple measurements will be aggregated by the study team to select a single recommended schedule of AB001. Single Outcome Measure Value (Units): AB001 Schedule in Cycles/weeks |
Countries
United States
Contacts
STUDY_CHAIRCMO
ARTBIO Inc.
Outcome results
None listed